Keyphrases
Acute Myeloid Leukemia Relapse
19%
Adult Humans
19%
Allogeneic Hematopoietic Cell
19%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
19%
Ataxia Telangiectasia
19%
Bone Marrow Microenvironment
19%
Calreticulin
19%
Cell State
21%
Clear Cell Renal Cell Carcinoma (ccRCC)
64%
Clinical Decision-making
19%
Clinical Routine
19%
Expression Atlas
19%
Glioblastoma
19%
Glioma
19%
HIF-2
38%
Hypomethylating Agents
19%
Hypoxia
14%
Hypoxia-inducible factor-1α (HIF-1α)
21%
Immune Escape
19%
Inhibitor Resistant
19%
Intratumoral Heterogeneity
19%
Malignant Progression
19%
Molecular Diagnostics
18%
Molecular Heterogeneity
19%
Molecular Tumor Board
38%
Myeloproliferative Neoplasms
15%
Niche Formation
19%
Nivolumab
19%
Off-label Use
9%
Phase II Trial
19%
Rad3
19%
Regulatory T Cells
19%
Renal Cell Carcinoma
19%
Single-center Experience
19%
Small Intestine
19%
Spatial Analysis
19%
Spatial Expression
19%
Spatial Proteomics
9%
Sphingosine 1-phosphate Signalling
19%
Stable Disease
12%
T Cell Expansion
19%
T Cells
11%
TGF-1
19%
Therapeutic Effect
19%
Treatment Recommendations
17%
Tumor
32%
Tumor Development
19%
Tumor Heterogeneity
38%
Tumor Inflammation
19%
Villi
14%
Medicine and Dentistry
Acute Myeloid Leukemia
19%
Biological Marker
6%
Carcinogenesis
5%
Cell Transplantation
15%
Chemotherapy
9%
Cisplatin
9%
Clear Cell Renal Cell Carcinoma
57%
Clinical Decision Making
19%
Combination Therapy
6%
Diagnosis
7%
Disease
20%
DNA Damage
19%
Exome Sequencing
19%
Hematopoietic Cell
19%
Hypomethylating Agent
19%
Image Analysis
19%
Immunity
10%
Lethality
19%
Leukemia Relapse
19%
Malignant Neoplasm
40%
Metastatic Carcinoma
19%
Molecular Diagnostics
7%
Neoplasm
100%
Overall Survival
6%
Patient Compliance
7%
Personalized Medicine
7%
Phase II Trials
19%
Primary Tumor
19%
RNA Sequence
6%
T Cell
6%
Transcriptomics
5%
